View Clinical Trial (Medical Research Study)


A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease - NCT00501059-53218(Clinical Trial 177015)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Milwaukee
State:  
WI
Zip Code: 53218
Conditions: Moderate Risk of CVD
Purpose: The use of acetylsalicylic acid in the primary prevention of cardiovascular events has been extensively studied. However, the overall risk level of the study populations was low (< 10% 10-year). The current study is designed to proof the efficacy and tolerability of 100 mg enteric-coated Aspirin versus placebo in the prevention of cardiovascular disease (CVD) events, which include fatal and nonfatal myocardial infarction, fatal and nonfatal stroke and CV death, in a population with no history of known CVD who are at moderate risk (20-30% 10-year) of cardiovascular disease. Subjects are treated in a standard care setting and may receive treatment of the underlying risk factors as defined by the treating physician. Outcome events will be adjudicated by an Endpoint Adjudication Committee and the study will be monitored by an independent Data Safety Monitoring Board.
Study summary:
Criteria: Inclusion Criteria: - Males aged 55 years and above with 2 to 4 risk factors Male Risk Factors - Elevated cholesterol (Tchol>200 mg/dL or LDL>130 mg/dL; as measured at screening) irrespective of current treatment - Current smoking: defined as any cigarette smoking in the past 12 months - Low HDL cholesterol (HDL<40 mg/dL; as measured at screening) - Elevated blood pressure (SBP>140 mmHg; as measured at screening) - Currently on any medication to treat high blood pressure - Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years) - Females aged 60 and above with 3 or more risk factors Female Risk Factors - Elevated cholesterol (Tchol>240 mg/dL or LDL>160 mg/dL; as measured at screening) irrespective of current treatment - Current smoking: defined as any cigarette smoking in the past 12 months - Low HDL cholesterol (HDL<40 mg/dL; as measured at screening) - Elevated blood pressure (SBP>140 mmHg; as measured at screening) - Currently on any medication to treat high blood pressure - Positive family history of early CHD (a first-degree relative [father, mother, brother, sister, son, daughter] suffered a heart attack [myocardial infarction] before the age of 60 years) - An understanding and willingness to comply with trial procedures and has given written informed consent to participate in the trial Exclusion Criteria: - Clinical history of CVD, MI, stroke, coronary artery angioplasty or stenting, coronary artery bypass graft, relevant arrhythmias, or congestive heart failure or - Patients who are at higher than moderate risk on the basis of their diabetes status, other factors known to the investigator, or the currently used national risk score - Known contraindications to the study drug, e.g. hypersensitivity to acetylsalicylic acid - Increased risk of bleeding or gastric or duodenal ulcer, or current /diagnosed reflux esophagitis - Patients presenting with any medical condition, or psychiatric or substance abuse disorder, that, in the opinion of the investigator, is likely to affect the patients ability to complete the study or precludes the patients participation in the study - Lactating women or women of childbearing potential - Severe liver disease or damage, or moderately impaired renal function based on the clinical judgment of the investigator - A definite indication for acetylsalicylic acid therapy, other anti-platelet drug, or anticoagulant in the opinion of the physician - A history of asthma induced by administration of salicylates or substances with similar action, notably NSAIDS - Chronic, frequent (> 5 days/month) use of NSAIDs, COX 2 inhibitors or metamizole, or current participation in any other trials involving investigational products within 30 days prior to the Screening Visit
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: August 16, 2010
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.